Zafgen pharma

Boston, MA 02114

Zafgen Pharma, located in the heart of Boston, MA, is a pharmaceutical company focused on developing innovative treatments for diseases related to metabolism. With a commitment to scientific excellence, Zafgen aims to improve patient outcomes through cutting-edge research and development. The team at Zafgen strives to deliver effective solutions to meet the needs of those suffering from metabolic disorders.

Generated from this place's information

Own this business?

See a problem?

Real estate managers

Beacon Press

Beacon Press is an independent book publisher based in Boston, specializing in non-fiction subjects like religion, history, current affairs, political science, gender studies, and education. The company is known for its focus on thought-provoking and socially relevant literature. With a commitment to publishing diverse voices and perspectives, Beacon Press aims to provide readers with insightful and impactful works that contribute to the intellectual discourse on important issues in society. Generated from their available business information

Feathers and feather products, Real estate managers, Drugs acting on the respiratory system

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a biopharmaceutical company based in Cambridge, MA, specializing in the development of novel cancer therapies. The company focuses on targeting epigenetic pathways to discover and advance potential treatments for various types of cancer. Utilizing cutting-edge research and technology, Constellation Pharmaceuticals is dedicated to advancing the field of oncology through innovative drug discovery and development. The company's mission is to improve patient outcomes and make a meaningful impact in the fight against cancer. Generated from their business information

Sizes, Services, nec, nec, Business services, nec, nec

Merrimack Pharmaceuticals

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website